Ad
related to: does simvastatin cause a cough
Search results
Results From The WOW.Com Content Network
Simvastatin, sold under the brand name Zocor among others, is a statin, a type of lipid-lowering medication. [4] It is used along with exercise, diet, and weight loss to decrease elevated lipid levels . [ 4 ]
Statin-induced hepatotoxicity can cause autoimmune hepatitis and an elevation in serum levels of hepatic enzymes such as alanine aminotransferase, impairing liver function. [20] Myotoxicity is commonly presented with statin-associated muscle symptoms (SAMS), which include myalgia and myositis. [21]
Fibrates may decrease LDL, though generally to a lesser degree than statins. Similar to statins, the risk of muscle damage exists. Nicotinic acid, like fibrates, is also well suited for lowering triglycerides by 20–50%. It may also lower LDL by 5–25% and increase HDL by 15–35%. Niacin may cause hyperglycemia and may also cause liver damage.
“In adults over the age of 65, symptoms almost always include a cough, whereas with the flu, coughing is usually just present in about two-thirds of patients,” he says.
Muscle pain and other symptoms often cause patients to stop taking a statin. [87] This is known as statin intolerance. A 2021 double-blind multiple crossover randomized controlled trial (RCT) in statin-intolerant patients found that adverse effects, including muscle pain, were similar between atorvastatin and placebo. [ 88 ]
These antibodies are known to also occur in people who do not take statin medications. [3] Conversely, these antibodies are absent in people who take statin medications but do not have myopathy. Thus, the presence of anti-HMG CoA reductase antibodies in someone who uses a statin and has myopathy strongly supports the diagnosis. [3]
cough; memory loss or forgetfulness; confusion; The following rare side effects are more serious. Like all statins, rosuvastatin can possibly cause myopathy, rhabdomyolysis: [14] [4] muscle pain, tenderness, or weakness; lack of energy; fever; chest pain; jaundice: yellowing of the skin or eyes; dark colored, or foamy urine; pain in the upper ...
With median follow-up of 6 years, simvastatin+ezetimibe was found to reduce the primary outcome of CV mortality, major CV event, or nonfatal stroke (34.7% vs. 32.7%; P=0.016; NNT 50 per 7 years or NNT 350 per 1 year ). There was no reduction in all-cause or CV mortality with simvastatin+ezetimibe, though there was a reduction in MI and stroke. [6]